Originally approved for HIV-associated lipodystrophy, it has shown consistent visceral fat reduction in multiple trials in non-HIV adults a meaningful benefit given visceral adiposity's role in cardiovascular and metabolic risk after 60.2 BPC-157 Body Protection Compound-157 is a synthetic peptide derived from a gastric protein
Ingredients: Water, Ethylhexyl Methoxycinnamate, Betaine, Glyceryl Stearate, Cetyl Alcohol, PEG-100 Stearate, C12-15 Alkyl Benzoate, Titanium Dioxide, Alumina, Polyhydroxystearic Acid, Isopropyl Titanium Triisostearate/Triethoxycaprylylsilane Crosspolymer, Paeonia Suffruticosa Root Extract, Scutellaria Baicalensis Root Extract, Saxifraga Sarmentosa Extract, Acetyl Tyrosine, Butylene Glycol, Arbutin, Citric Acid, Sodium Sulfite, Glutathione, Aminopropyl Ascorbyl Phosphate, Palmitic Acid, Stearic Acid, Glycerin, Glycol Stearate, Caprylic/Capric Triglyceride, Hydrogenated Polydecene, Cyclotetrasiloxane, Cyclopentasiloxane, Isopropyl Palmitate, Aluminum Starch Octenylsuccinate, PEG-75 Stearate, Ceteth-20, Steareth-20, Niacinamide, Fragrance, Phenoxyethanol, Caprylyl Glycol, Butyrospermum Parkii Butter, Kojic Acid, Saccharide Isomerate, Sodium Citrate, Triethanolamine, Butyl Methoxydibenzoylmethane, Tetrasodium EDTA, Carbomer
Machine learning-based prediction of diabetic peripheral neuropathy: model development and clinical validation
Ethics declarations Conflict of interest The authors declare that they have no conflict of interest
Among these, C1QA, the initiating protein of the classical pathway, plays a critical role in neurodegenerative and psychiatric disorders
Each tested combination was analyzed in triplicate independent replicates
